Biocure Technology (XCNQ:CURE) EV-to-EBIT : -1.04 (As of Jun. 05, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biocure Technology's Enterprise Value is C$1.49 Mil. Biocure Technology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$-1.43 Mil. Therefore, Biocure Technology's EV-to-EBIT for today is -1.04.

The historical rank and industry rank for Biocure Technology's EV-to-EBIT or its related term are showing as below:

XCNQ:CURE' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.86 Med: -3.51 Max: -0.66
Current: -1.04

During the past 13 years, the highest EV-to-EBIT of Biocure Technology was -0.66. The lowest was -12.86. And the median was -3.51.

XCNQ:CURE's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 9.61 vs XCNQ:CURE: -1.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Biocure Technology's Enterprise Value for the quarter that ended in Mar. 2024 was C$1.45 Mil. Biocure Technology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$-1.43 Mil. Biocure Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -98.48%.

Biocure Technology EV-to-EBIT Historical Data

The historical data trend for Biocure Technology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology EV-to-EBIT Chart

Biocure Technology Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-5.31

-10.96

-9.56

-1.97

-0.97

Biocure Technology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-11.17	1.20	0.55	-0.97	-1.02

Competitive Comparison of Biocure Technology's EV-to-EBIT

For the Biotechnology subindustry, Biocure Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocure Technology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocure Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biocure Technology's EV-to-EBIT falls into.

Biocure Technology EV-to-EBIT Calculation

Biocure Technology's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1.490	/	-1.428
	=	-1.04

Biocure Technology's current Enterprise Value is C$1.49 Mil.
Biocure Technology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.43 Mil.

Biocure Technology (XCNQ:CURE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Biocure Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-1.428	/	1.4500075
	=	-98.48 %

Biocure Technology's Enterprise Value for the quarter that ended in Mar. 2024 was C$1.45 Mil.
Biocure Technology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.43 Mil.

Biocure Technology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Biocure Technology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocure Technology (XCNQ:CURE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9

Website

https://www.biocuretech.com

Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It is in the process of preclinical trials of five majorly biosimilar products in South Korea, including Interferon Beta 1b, PEGFilgrastim, and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.